Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Akero Therapeutics Inc (AKRO)
NASDAQ:AKRO
Holding AKRO?
Track your performance easily
AKRO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.25 - $53.77
Previous Close$27.2
Volume484.64K
Average Volume (3M)745.23K
Market Cap
$1.87B
Enterprise Value$1.14B
Total Cash (Recent Filing)$760.19M
Total Debt (Recent Filing)$35.64M
Price to Earnings (P/E)―
Beta-0.39
Next Earnings
Nov 13, 2024EPS Estimate
-$0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.41
Shares Outstanding69,430,754
10 Day Avg. Volume495,713
30 Day Avg. Volume745,233
Standard Deviation0.31
R-Squared0.00232
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)2.21
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-13.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.70
Forecast
1Y Price Target
$48.33Price Target Upside77.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Akero Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe initiation of SYNCHRONY Outcomes marks the active progress of all three Phase III clinical trials for efruxifermin (EFX) in MASH patients.
Drug DevelopmentEfruxifermin is considered one of the most exciting MASH drug candidates in development, with strong potential to benefit a wider range of MASH patients.
Financial ResourcesAkero's financial resources are sufficient to fund the SYNCHRONY Histology and SYNCHRONY Real-World studies through their primary readouts, supporting the company's plans into the second half of 2027.
Bears Say
Clinical ResultsPh2b SYMMETRY trial results showed clinical failure of EFX vs placebo in fibrosis improvement.
Clinical TrialsHigher rate of discontinuations at Week 96 in SYMMETRY compared to HARMONY expected due to more advanced enrolled patients.
Financial RisksKey risks include failed or equivocal trial results, unforeseen safety or tolerability issues, meaningful delays to expected timelines, or inability to sufficiently fund operations.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
AKRO FAQ
What was Akero Therapeutics Inc’s price range in the past 12 months?
Akero Therapeutics Inc lowest stock price was $11.25 and its highest was $53.77 in the past 12 months.
What is Akero Therapeutics Inc’s market cap?
Currently, no data Available
When is Akero Therapeutics Inc’s upcoming earnings report date?
Akero Therapeutics Inc’s upcoming earnings report date is Nov 13, 2024 which is in 74 days.
How were Akero Therapeutics Inc’s earnings last quarter?
Akero Therapeutics Inc released its earnings results on Aug 09, 2024. The company reported -$0.81 earnings per share for the quarter, beating the consensus estimate of -$0.83 by $0.02.
Is Akero Therapeutics Inc overvalued?
According to Wall Street analysts Akero Therapeutics Inc’s price is currently Undervalued.
Does Akero Therapeutics Inc pay dividends?
Akero Therapeutics Inc does not currently pay dividends.
What is Akero Therapeutics Inc’s EPS estimate?
Akero Therapeutics Inc’s EPS estimate is -$0.85.
How many shares outstanding does Akero Therapeutics Inc have?
Akero Therapeutics Inc has 69,430,756 shares outstanding.
What happened to Akero Therapeutics Inc’s price movement after its last earnings report?
Akero Therapeutics Inc reported an EPS of -$0.81 in its last earnings report, beating expectations of -$0.83. Following the earnings report the stock price went down -0.762%.
Which hedge fund is a major shareholder of Akero Therapeutics Inc?
Among the largest hedge funds holding Akero Therapeutics Inc’s share is Perceptive Advisors LLC. It holds Akero Therapeutics Inc’s shares valued at 35M.
---
Akero Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.33 (77.68% Upside)
$48.33 (77.68% Upside)
Blogger Sentiment
Bullish
AKRO Sentiment 71%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $417.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-45.28%
12-Months-Change
Fundamentals
Return on Equity
-28.87%
Trailing 12-Months
Asset Growth
30.32%
Trailing 12-Months
Company Description
Akero Therapeutics Inc
Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.
---
AKRO Stock 12 Month Forecast
Average Price Target
$48.33
▲(77.68% Upside)
Technical Analysis
Best Analysts Covering AKRO
1 Year
1 Year Success Rate
10/19 ratings generated profit
1 Year Average Return
+10.94%
reiterated a buy rating 21 days ago
Copying Edward Nash's trades and holding each position for 1 Year would result in 52.63% of your transactions generating a profit, with an average return of +10.94% per trade.
---